Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have earned a consensus rating of “Buy” from the seventeen research firms that are covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $56.71.
ESPR has been the subject of a number of research analyst reports. ValuEngine upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Citigroup Inc. reiterated a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, June 22nd. Jefferies Group LLC initiated coverage on Esperion Therapeutics in a report on Monday, July 10th. They set a “hold” rating and a $55.00 price target for the company. Cowen and Company initiated coverage on Esperion Therapeutics in a report on Thursday, September 7th. They set an “outperform” rating and a $64.00 price target for the company. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $60.00 price target (up from $45.00) on shares of Esperion Therapeutics in a report on Monday, June 26th.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Lord Abbett & CO. LLC acquired a new stake in Esperion Therapeutics in the 2nd quarter valued at about $6,432,000. Tower Research Capital LLC TRC raised its position in Esperion Therapeutics by 69,371.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 4,856 shares in the last quarter. RA Capital Management LLC raised its position in Esperion Therapeutics by 3.8% in the 2nd quarter. RA Capital Management LLC now owns 731,531 shares of the biopharmaceutical company’s stock valued at $33,855,000 after purchasing an additional 26,830 shares in the last quarter. State Street Corp raised its position in Esperion Therapeutics by 264.6% in the 2nd quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock valued at $69,721,000 after purchasing an additional 1,093,292 shares in the last quarter. Finally, Macquarie Group Ltd. acquired a new stake in Esperion Therapeutics in the 2nd quarter valued at about $1,182,000. 83.30% of the stock is currently owned by hedge funds and other institutional investors.
Esperion Therapeutics (ESPR) traded down 0.12% on Friday, reaching $49.31. 412,757 shares of the company’s stock traded hands. The stock’s market capitalization is $1.11 billion. Esperion Therapeutics has a 52 week low of $9.40 and a 52 week high of $57.38. The firm has a 50-day moving average price of $48.34 and a 200-day moving average price of $40.88.
Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.67) by ($0.25). During the same quarter in the prior year, the firm posted ($0.62) earnings per share. On average, analysts predict that Esperion Therapeutics will post ($7.29) earnings per share for the current year.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.